Yurong Peng
Overview
Explore the profile of Yurong Peng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
133
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang X, Ling R, Peng Y, Qiu W, Chen D
Int J Oral Sci
. 2024 Jan;
16(1):6.
PMID: 38246918
Existing studies have underscored the pivotal role of N-acetyltransferase 10 (NAT10) in various cancers. However, the outcomes of protein-protein interactions between NAT10 and its protein partners in head and neck...
2.
Zhang C, Guo J, Yin H, Yin C, Peng Y
J Ethnopharmacol
. 2023 Oct;
319(Pt 3):117317.
PMID: 37832809
Ethnopharmacological Relevance: Although therapeutic hypothermia is currently considered an effective treatment for neonatal hypoxic-ischemic encephalopathy (HIE), neonatal HIE is a disease requiring multiple therapeutic measures. Related Chinese herbal injections (CHIs)...
3.
Xiao C, Xiong W, Xu Y, Zou J, Zeng Y, Liu J, et al.
Front Med
. 2023 Sep;
17(4):585-616.
PMID: 37725232
Immune checkpoint inhibitors (ICIs) have demonstrated unparalleled clinical responses and revolutionized the paradigm of tumor treatment, while substantial patients remain unresponsive or develop resistance to ICIs as a single agent,...
4.
Peng Y, Li Z, Fu Y, Pan Y, Zeng Y, Liu J, et al.
Front Oncol
. 2023 Apr;
13:1163376.
PMID: 37064096
[This corrects the article DOI: 10.3389/fonc.2023.1011810.].
5.
Wang S, Li Y, Liu Z, Tian W, Zeng Y, Liu J, et al.
Lung Cancer
. 2023 Feb;
178:47-56.
PMID: 36774774
The efficacy and safety of first-line immune checkpoint inhibitors plus chemotherapy in the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) remains unevaluated, and there are no reports...
6.
Peng Y, Li Z, Fu Y, Pan Y, Zeng Y, Liu J, et al.
Front Oncol
. 2023 Feb;
13:1011810.
PMID: 36761954
Lung cancer is one of the leading causes of cancer-related death. Lung cancer mortality has decreased over the past decade, which is partly attributed to improved treatments. Curative surgery for...
7.
Hu C, Zhao L, Zhou C, Wang H, Jiang S, Li Y, et al.
Open Med (Wars)
. 2022 Dec;
17(1):2109-2116.
PMID: 36582209
Immune-related cardiotoxicities are uncommon but potentially fatal. The study aims to evaluate the value of pacemakers and methylprednisolone pulse therapy (MPPT) to patients with immune-related myocarditis concomitant with complete heart...
8.
Zou J, Zhang Y, Zeng Y, Peng Y, Liu J, Xiao C, et al.
Cancers (Basel)
. 2022 Dec;
14(23).
PMID: 36497450
A tertiary lymphoid structure (TLS) is a special component in the immune microenvironment that is mainly composed of tumor-infiltrating lymphocytes (TILs), including T cells, B cells, DC cells, and high...
9.
Liu Y, Zeng Y, Li Y, Ke J, Pan Y, Liu X, et al.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
. 2022 Nov;
47(9):1281-1288.
PMID: 36411713
Chronic stress is a serial of non-specific neuroendocrine reactions in the body when stimulated by stressors for a long time, which has been shown to have a significant effect on...
10.
Tian Z, Zeng Y, Peng Y, Liu J, Wu F
Front Immunol
. 2022 Nov;
13:996663.
PMID: 36353640
Activation of the cGAS-STING pathway by cytoplasmic DNA induces the production of Type-1 interferons. Recent advances in research suggest that the cGAS-STING pathway is involved in different parts of the...